1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
  1. 5-HT2A

    The Food and Drug Administration is likely to approve a phase three clinical trial of MDMA-assisted psychotherapy, according to the Multidisciplinary Association for Psychedelic Studies (MAPS), which met with the agency on May 11. A successful phase three trial--i.e., a randomly controlled, double-blinded study that demonstrates both efficacy and safety in a large patient population--would all but guarantee the drug's eventual removal from schedule I of the Controlled Substances Act.

    "At the meeting, all of the FDA's concerns were addressed and no outstanding questions remain," MAPS reported after its sit-down with the FDA earlier this month. "There are no roadblocks to moving forward with Phase 3 as the FDA gave favorable feedback to MAPS and [MAPS Public Benefit Corporation's] responses to FDA questions."

    The FDA will share official minutes with MAPS in mid-June, after which the group will re-submit its protocol and Statistical Analysis Plan. It expects both will be approved without objection.

    The phase three trial for MDMA-assisted psychotherapy as a treatment for PTSD is expected to cost approximately $25 million, of which MAPS has already raised $10 million (none of it from government agencies or pharmaceutical companies.)

    There's a lot at stake here. In addition to the outrageous criminal penalties associated with schedule I substances, MDMA has incredible potential as a treatment for a range of central nervous system disorders:

    Original Source

    Written by: Mike Riggs, May 17, 2017, MDMA Moves One Step Closer to Phase 3 Clinical Trial, Reason

Recent User Reviews

  1. detoxin momma
    4/5, 4 out of 5, reviewed May 20, 2017
    4/5 only because still missing italics


  1. dr ACE
    Most excellent news.let the healing begin
To make a comment simply sign up and become a member!